FDA grants accelerated approval to AbbVie’s Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.
FDA Fast-Tracks AbbVie’s New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
Where Today's News Shapes Tomorrow
